Astellas is a pharmaceutical company committed to Changing tomorrow, turning innovative science into value for patients across a range of therapeutic areas.
Astellas uses its agility to match scientific breakthroughs to the unmet medical needs of people around the world, and the many healthcare professionals and caregivers who support them.
Astellas invests in new medicines, technologies and therapeutic areas, and builds partnerships and networks with others who share its vision to improve the future of medicine.
Astellas is on the forefront of healthcare change and its values of patient focus, ownership, results, openness and integrity are the foundation of its culture, guiding everything that it does.
Please visit the Astellas UK website for further information: www.astellas.com/uk
Chugai Pharma UK is part of the Chugai Group’s European hub and has been bringing novel therapies to patients since 1993. Headquartered in London, our mission is to add exceptional value through the delivery of innovative medical products and services for the benefit of the medical community and society. Current therapy areas include oncology, immunology and haemophilia.
Chugai Pharma Europe is the Headquarters of the European hub, also based in London, we employ over 250 highly-skilled experts, with offices in the UK, Germany and France.
Please visit the Chugai Pharma Europe website for further information: www.chugai.co.uk
Daiichi Sankyo UK Ltd is a UK affiliate company with corporate origins in Japan. We create and supply innovative products to help the NHS to deliver better patient care in the fields of cardiovascular disease and oncology.
Our company was founded in 2006 through the merger of Japanese companies Daiichi and Sankyo in Europe. With a rich legacy of scientific expertise dating back more than 100 years, we are the pioneer behind leading pharmaceuticals that have contributed to the improvement of countless lives across the world.
Our mission is to contribute to the enrichment of quality of life through the discovery and delivery of innovative medicines that address diverse and unmet medical needs.
We are committed to providing innovation that demonstrates value and supports the NHS in its delivery of sustainable high-quality care, enabling efforts to reduce health inequalities and unwarranted variations and which puts the patient at the heart of the service.
Please visit the website for further information: www.daiichi-sankyo.co.uk
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
Please visit the website for more information about Eisai in EMEA: www.eisai.eu
Kyowa Kirin is a Japan-based, global specialty pharmaceutical company dedicated to contributing to human health and well-being worldwide. Kyowa Kirin International (KKI), headquartered in Marlow, Buckinghamshire, is its regional base with responsibility for business in Europe, the United Kingdom, and the Middle East. Kyowa Kirin Limited, located in Galashiels, South Borders, Scotland, is our UK affiliate.
We focus on supporting patients and families living with diseases for which no effective treatments are available. Our purpose is to make people smile.
Our business vision is fulfilled through diligent and continuous efforts to bring innovative pharmaceuticals to patients, utilizing our R&D expertise, knowledge and more specifically our state-of-the-art antibody technologies in our core therapeutic areas of oncology, nephrology, central nervous system and immunology.
We recognize that accessing and pursuing external opportunities for our R&D activities is an indispensable and essential aspect of our strategy to establish a solid pipeline of products. We deeply believe that "Open Innovation" is essential for drug discovery and actively seek research collaboration opportunities, and innovative technologies for accelerating drug development. We are open and flexible to strategic collaborations or partnerships with pharmaceuticals, biotech, and academia partners.
Our values shape the company we are and guide our actions:
Innovation: We transform lives with passion and excitement and challenge the status quo in all our work.
Teamwork/Wa: One for all, all for one. We work in diverse teams that respect one another. We go beyond boundaries and collaborate with stakeholders.
Integrity: We're committed to doing the right thing, always. We act with sincerity, honesty, and high ethical standards, striving to make the world a better place through good business practices.
Commitment to Life: We're dedicated to doing everything we can to improve the quality of life for people around the world.
As we face the challenges of a rapidly changing industry, we stay committed to scientific excellence and improving lives.
Please visit the websites for further information: kyowa-kirin.com; www.international.kyowa-kirin.com/uk
Mitsubishi Tanabe Pharma Europe acts as the European Headquarters of one of Japan’s leading pharmaceutical companies, Mitsubishi Tanabe Pharma Corporation. Based in London, we are dedicated to the clinical development of new medicines for the European markets. We are marketing authorisations holder and also support commercial operations for other in-house products.
Please visit the website for further information: www.mt-pharma-eu.com
Upholding the corporate philosophy “Dedicated to the Fight against Disease and Pain,” Ono takes on the challenge against diseases that have not yet been overcome, and disease areas which have a low level of patient satisfaction with current treatment and/or high medical need. We are endeavoring to make creative and innovative drugs.
ONO PHARMA UK LTD. (OPUK) was established in 1998 as the Europe subsidiary of Ono Pharmaceutical Co., Ltd., an R&D-oriented pharmaceutical company with a headquarters in Osaka, Japan.
In Europe, we currently have an organisation focused mainly on medicines development. We will continue to improve and strengthen this, to build an extensive in-house development capability, working from late-stage clinical trials to regulatory filing.We have succeeded in delivery of "first in class" cancer medicine to patients, with immunotherapy for a wide range of cancers. Our products have often been marketed in Europe through partnerships with other pharmaceutical companies with an established commercial presence.
Going forward and considering the encouraging status of ongoing clinical trials, we are realising our goal to become a global company that can compete on the world stage, with the establishment of our own commercial teams in Europe.
Please visit the website for further information: https://uk.ono-pharma.com
Otsuka Pharmaceuticals (UK) Ltd. (OPUK) established its presence in the UK in 1998. It is an affiliate organisation of Otsuka Pharmaceutical Europe Ltd (OPEL) which has been in Europe since 1974. OPUK and OPEL are situated in Buckinghamshire, United Kingdom, and are part of Otsuka Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo. OPUK works in the areas of mental health, nephrology and oncology. More broadly OPEL is also exploring how to better support patient’s care and treatment by leveraging new therapies, technologies and digital solutions.
Please visit the website for further information: www.otsuka-europe.com/uk
As a specialised company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products and devices. We are a conscientious organisation, dedicated to working with the ophthalmology community and partners to improve eye health and vision, with the societal benefits that brings. Santen has long been the market leader in Japan for prescription ophthalmic pharmaceuticals and is now a leader in the sector in the EMEA (Europe, Middle East and Africa) region. We are constantly growing and improving our range of medicines and technologies because we care deeply about applying science to help patients with eye health concerns. With scientific knowledge and organisational capabilities nurtured over nearly 130 years, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society in more than 60 countries.
Please visit the website for further information: www.santen.uk
Shionogi was founded in 1878 by Gisaburo Shiono SR. in Doshomachi, Osaka, Japan. Today the headquarters of Shionogi & Co., Ltd are still in Osaka but the company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care.
Our European company is registered Amsterdam where the regional headquarters are also based. European operations are mainly situated in London.
Shionogi is committed to putting patients first by developing innovative, high-quality medicines which address their unmet needs and improve the quality of their lives. Our R&D efforts focus on therapeutic areas where we have proven expertise and can make an impact. These include infectious disease, haematology, women’s health pain and CNS disorders.
We are proud to have delivered breakthrough treatments in these therapeutic areas and aim to find even better solutions to major global public health concerns using our advanced scientific know-how, talented people and passion.
Our values are at the heart of everything we do. They define our culture, shape our collaborative approach to R&D, and guide our decision-making so that we can achieve our global vision of “building innovation platforms to shape the future of healthcare.”
Please visit the website for further information: www.shionogi.eu
Sosei Heptares is an international biopharmaceutical group with headquarters in Tokyo, Japan and R&D facilities in Cambridge, UK. Sosei Heptares is focused on the discovery and development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
Sosei Heptares has established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily.
Please visit the website for further information: www.soseiheptares.com/home
Takeda Pharmaceutical Company Limited is headquartered in Japan and is a global, values-based, R&D-driven biopharmaceutical leader committed to translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Additional information about Takeda UK Ltd. is available through its corporate website: www.takeda.com/en-gb